MedPath

Videothoracoscopic (VATS) vs. Robotic Approach for Lobectomy or Anatomical Segmentectomy

Not Applicable
Conditions
Lung Cancer
Interventions
Procedure: VATS
Procedure: RATS
Registration Number
NCT02804893
Lead Sponsor
Istituto Clinico Humanitas
Brief Summary

This is a prospective, randomized, multicenter study on 300 patients (150 VATS lobectomies and 150 robotic lobectomies) affected by early stage (I-II) lung cancer. The expected recruitment is one year and two year follow up. Surgeons should have a minimum of 30 major lung resections performed using one of the two techniques for participation in the study. Each participating centers should have the possibility to offer both techniques (Robotics and Vats). The primary end point is a combination of conversion and complication rate. The presence of at least one of the two events is considered a failure. Considering the rate of failure of 35% in the VATS arm, we want to see a failure rate not over 20% in the robot arm, so with a power of 80% and an alpha error of 5%, we need a total of 300 patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Age older than 18 years old
  • Known or suspected lung cancers
  • Patients in clinical stage T1-T2, N0-N1 candidate to surgery lobectomy or anatomical segmentectomy
  • ASA-1-2-3
Exclusion Criteria
  • Clinical stage >II
  • Severe heart disease
  • Alcohol abuse
  • Renal impairment (creatinine >2.5)
  • Presence of serious comorbidities

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VATS GROUPVATSVATS lobectomy or segmentectomy
RATS GROUPRATSRobotic lobectomy or segmentectomy
Primary Outcome Measures
NameTimeMethod
Postoperative complications: surgical complications, higher or equal grade II assessed by Clavien-Dindo scale, within 90 dayswithin 90 days
Intraoperative complications: conversion rate, defined as procedures that start with minimally invasive access and are converted to open surgery due to different reasons (bleeding, anatomical reasons, oncological reasons, technical reasons, other)date of Surgery
Secondary Outcome Measures
NameTimeMethod
Duration of analgesic use after discharge and time to return to normal daily activitywithin 90 days
Rate of local and distant recurrence and disease free survival24 months
Patient's immune response: analysis of PCR, serum interleukins, lymphocytes subpopulationsbefore surgery, 2 hours after surgery and at 3rd and 14th postoperative day
Proportion of patients who undergo complete resection during the proceduredate of Surgery
Postoperative hospital stay2 weeks
Number of resected lymph nodes and upstagingdate of Surgery
Postoperative pain: daily evaluation with visual numeric scale before and after surgery until discharge2 weeks, 6 months and 12 months
Duration of surgerydate of Surgery
Quality of life by EORTC QOL-C302 weeks, 6 months and 12 months
Postoperative respiratory function: FEV 1, PEF and CV6 month postoperatively

Trial Locations

Locations (1)

Thoracic surgery Division, Istituto Clinico Humanitas

🇮🇹

Rozzano, Milan, Italy

© Copyright 2025. All Rights Reserved by MedPath